These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 32291401)

  • 1. Comparison of the outcomes of photodynamic therapy for central serous chorioretinopathy with or without subfoveal fibrin.
    Liang Z; Qu J; Huang L; Linghu D; Hu J; Jin E; Xu H; Li H; Tao Y; Xu X; Liu G; Li Y; Zhao M
    Eye (Lond); 2021 Feb; 35(2):418-424. PubMed ID: 32291401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison between the outcomes of fluorescein angiography-guided and indocyanine green angiography-guided half-time photodynamic therapy for central serous chorioretinopathy.
    Hayashida M; Miki A; Honda S; Nakamura M
    Photodiagnosis Photodyn Ther; 2020 Sep; 31():101955. PubMed ID: 32818640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up.
    Arevalo JF; Espinoza JV
    Graefes Arch Clin Exp Ophthalmol; 2011 Aug; 249(8):1159-66. PubMed ID: 21448811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of focal laser photocoagulation and photodynamic therapy for the treatment of central serous chorioretinopathy.
    Shin YI; Kim KM; Lee MW; Kim JY; Jo YJ
    Jpn J Ophthalmol; 2020 Jan; 64(1):28-36. PubMed ID: 31863228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multicenter Study on the Long-term Outcomes of Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy.
    Lai FH; Ng DS; Bakthavatsalam M; Chan VC; Young AL; Luk FO; Tsang CW; Brelén ME
    Am J Ophthalmol; 2016 Oct; 170():91-99. PubMed ID: 27519561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Observation on long-term efficacy of half-dose photodynamic therapy with chronic central serous chorioretinopathy using optical coherence tomography].
    Liu Y; Li L; Xu G; Wang W
    Zhonghua Yan Ke Za Zhi; 2016 May; 52(5):328-34. PubMed ID: 27220704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical research on one-third dose verteporfin photodynamic therapy in the treatment of chronic central serous chorioretinopathy.
    Hua L; Lin B; Hong J; Min HB; Han WL; Zhou TY; Zhang ZQ
    Eur Rev Med Pharmacol Sci; 2018 Jan; 22(2):278-284. PubMed ID: 29424884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
    Son BK; Kim K; Kim ES; Yu SY
    Ophthalmologica; 2019; 241(2):105-115. PubMed ID: 30110697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors of persistent subretinal fluid after half-dose photodynamic therapy for treatment-naïve central serous chorioretinopathy.
    Li M; Qu J; Liang Z; Tang J; Hu J; Yao Y; Jin E; Li X; Zhao M
    Graefes Arch Clin Exp Ophthalmol; 2022 Jul; 260(7):2175-2182. PubMed ID: 35024912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study.
    Silva RM; Ruiz-Moreno JM; Gomez-Ulla F; Montero JA; Gregório T; Cachulo ML; Pires IA; Cunha-Vaz JG; Murta JN
    Retina; 2013 Feb; 33(2):309-15. PubMed ID: 23095766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Half-fluence photodynamic therapy in acute central serous chorioretinopathy.
    Smretschnig E; Ansari-Shahrezaei S; Moussa S; Glittenberg C; Krebs I; Binder S
    Retina; 2012; 32(10):2014-9. PubMed ID: 22466482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of vessel density by optical coherence tomography angiography in patients with central serous chorioretinopathy after low-fluence photodynamic therapy.
    Cennamo G; Montorio D; Comune C; Clemente L; Iovino C; Carandente R; Tranfa F
    Photodiagnosis Photodyn Ther; 2020 Jun; 30():101742. PubMed ID: 32198017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COMPARISON OF VISUAL/ANATOMICAL OUTCOMES AND RECURRENCE RATE BETWEEN ORAL SPIRONOLACTONE AND PHOTODYNAMIC THERAPY FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY.
    Kim DY; Lee JY; Lee EK; Kim JY
    Retina; 2020 Jun; 40(6):1191-1199. PubMed ID: 30897068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Focal and Conventional Verteporfin Photodynamic Therapy for Chronic Central Serous Chorioretinopathy.
    Noh SR; Kang MS; Kim K; Kim ES; Yu SY
    Korean J Ophthalmol; 2019 Dec; 33(6):506-513. PubMed ID: 31833247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year results of half-dose versus one-third-dose photodynamic therapy in chronic or recurrent central serous chorioretinopathy.
    Pichai J; Vanchalerm B; Mansing R
    BMC Ophthalmol; 2021 Jan; 21(1):30. PubMed ID: 33430812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Efficacy and Safety of Photodynamic Therapy in Patients With Chronic Central Serous Chorioretinopathy.
    Park YJ; Kim YK; Park KH; Woo SJ
    Ophthalmic Surg Lasers Imaging Retina; 2019 Dec; 50(12):760-770. PubMed ID: 31877221
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optical coherence tomography angiography to assess vascular remodeling of the choriocapillaris after low-fluence photodynamic therapy for chronic central serous chorioretinopathy.
    Cennamo G; Cennamo M; Caputo G; Mirra F; Pafundi PC; de Crecchio G; Cennamo G
    Photodiagnosis Photodyn Ther; 2019 Sep; 27():162-166. PubMed ID: 31163282
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY.
    Cheng CK; Chang CK; Peng CH
    Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COMPARISON OF SHORT-TERM EFFICACY BETWEEN ORAL SPIRONOLACTONE TREATMENT AND PHOTODYNAMIC THERAPY FOR THE TREATMENT OF NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY.
    Lee JH; Lee SC; Kim H; Lee CS
    Retina; 2019 Jan; 39(1):127-133. PubMed ID: 29095358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative evaluation of choriocapillaris using optical coherence tomography and optical coherence tomography angiography in patients with central serous chorioretinopathy after half-dose photodynamic therapy.
    Yang HS; Kang TG; Park H; Heo JS; Park J; Lee KS; Choi S
    PLoS One; 2020; 15(1):e0227718. PubMed ID: 31929582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.